3.74
-0.06 (-1.58%)
| Penutupan Terdahulu | 3.80 |
| Buka | 3.85 |
| Jumlah Dagangan | 17,902 |
| Purata Dagangan (3B) | 12,623 |
| Modal Pasaran | 43,280,404 |
| Harga / Jualan (P/S) | 61.68 |
| Harga / Buku (P/B) | 2.37 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2024 |
| Margin Operasi (TTM) | -1,769.48% |
| EPS Cair (TTM) | -1.53 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -97.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 16.33% |
| Nisbah Semasa (MRQ) | 6.27 |
| Aliran Tunai Operasi (OCF TTM) | -2.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.13 M |
| Pulangan Atas Aset (ROA TTM) | -33.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -61.55% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | CollPlant Biotechnologies Ltd. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.13 |
|
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.16% |
| % Dimiliki oleh Institusi | 12.23% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Benjamin Edwards Inc | 30 Sep 2024 | 23,810 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 14.00 (D. Boral Capital, 274.33%) | Beli |
| Median | 12.50 (234.23%) | |
| Rendah | 11.00 (HC Wainwright & Co., 194.12%) | Beli |
| Purata | 12.50 (234.23%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 4.36 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 29 Nov 2024 | 11.00 (194.12%) | Beli | 4.48 |
| D. Boral Capital | 27 Nov 2024 | 14.00 (274.33%) | Beli | 4.25 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Nov 2024 | Pengumuman | COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE |
| 12 Nov 2024 | Pengumuman | COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |